Thursday, 28 November 2013

Pharma Drugs

Exenatide: For the adjunctive treatment of Type 2 diabetes mellitus
Mecasermin: For the treatment of growth failure due to Primary IGFD
Pramlintide: For the treatment of type I and type II diabetes
Tipranavir: For the adjunctive treatment of HIV-1 infections
Entecavir: For the treatment of chronic hepatitis B infections with evidence of active viral replication
Ibandronate: For the treatment and prevention of osteoporosis
Galsulfase: For the treatment of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)
Ramelteon: For the treatment of sleep-onset insomnia
Natalizumab: For the treatment of relapsing forms of multiple sclerosis
Nelarabine: For the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma
Bevacizumab: For the treatment of metastatic carcinoma of the colon or rectum
Cetuximab: For the treatment of EGFR-expressing, metastatic colorectal cancer
Azacitidine: For the treatment of several myelodysplastic syndrome subtypes including refractory and chronic myelomonocytic leukemias
Telithromycin: For the treatment of infections caused by bronchitis, bacterial sinusitis and Community-acquired pneumonia
Rifaximin: For the treatment of Travelers' diarrhea caused by noninvasive strains of Escherichia coli
Fosrenol, lanthanum carbonate; For the treatment of hyperphosphatemia related to kidney dysfunction
Trospium chloride: For the treatment of overactive bladder with symptoms of urge urinary incontinence
Cinacalcet: For the treatment of secondary hyperparathyroidism and hypercalcemia in parathyroid carcinoma patients
Solifenacin succinate: For the treatment of overactive bladder with symptoms of urge urinary incontinence
Eszopiclone: For the treatment of insomnia and sleep maintenance
Natalizumab: For the treatment of relapsing forms of multiple sclerosis (currently suspended in US)
clofarabine: For the treatment of acute lymphoblastic leukemia in pediatric patients
Erlotinib, OSI 774: For the treatment of advanced refractory metastatic non-small cell lung cancer
Pegaptanib: For the treatment of wet age-related macular degeneration
Zemaira (alpha1-proteinase inhibitor: For the treatment of alpha1-proteinase inhibitor deficiency (Alpha-1) and emphysema
Enfuvirtide: For the treatment of HIV-1 infection in combination with other antiretroviral agents
Fosamprenavir calcium: For the treatment of HIV infection in adults in combination with other antiretroviral agents
Atazanavir sulfate: For the treatment of HIV-1 infection in combination with other antiretroviral agents
Laronidase: For the treatment of Mucopolysaccharidosis I (MPS I) in subjects aged 5 to 65
Ibandronate: For the treatment and prevention of osteoporosis
Pegvisomant: Injectable formulation for the treatment of acromegaly
Bortezomib: Injectable agent for the treatment of multiple myeloma patients who have received at least two prior therapies
Agalsidase beta: For the treatment of Fabry disease in adult patients
Tadalafil: Oral agent for the treatment for erectile dysfunction
Memantine: For the treatment of moderate to severe dementia of the Alzheimer’s type
Palonosetron: For the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy
Aprepitant: For the treatment of nausea and vomiting associated with chemotherapy
Gefitinib: For the second-line treatment of non-small-cell lung cancer
Bortezomib: Injectable agent for the treatment of multiple myeloma patients who have received at least two prior therapies.
Gefitinib: For the second-line treatment of non-small-cell lung cancer

No comments:

Post a comment